| scholarly article | Q13442814 |
| P2093 | author name string | Mark D Stegall | |
| Manish J Gandhi | |||
| Byron H Smith | |||
| Carrie A Schinstock | |||
| Manuel A Moreno Gonzales | |||
| Natalie A Moore | |||
| Nong Y Braaten | |||
| P2860 | cites work | Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection | Q33382552 |
| Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma | Q33389111 | ||
| Bortezomib in kidney transplant recipients with antibody mediated rejection: three case reports | Q33389918 | ||
| Prospective evaluation of the toxicity profile of proteasome inhibitor-based therapy in renal transplant candidates and recipients | Q33402549 | ||
| The Functional Assessment of Cancer Therapy scale: development and validation of the general measure | Q34361336 | ||
| Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation | Q37142892 | ||
| Down-regulating humoral immune responses: implications for organ transplantation | Q38140607 | ||
| Early Changes in Kidney Distribution under the New Allocation System | Q40201517 | ||
| Bortezomib alone fails to decrease donor specific anti-HLA antibodies: even after one year post-treatment. | Q42731765 | ||
| Bortezomib alone fails to decrease donor specific anti-HLA antibodies: 4 case reports. | Q43044466 | ||
| Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection | Q43166691 | ||
| Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies | Q43178469 | ||
| Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation | Q43181339 | ||
| Five-year outcomes in living donor kidney transplants with a positive crossmatch. | Q45351621 | ||
| Assessing the efficacy of kidney paired donation--performance of an integrated three-site program | Q45851832 | ||
| Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation | Q46270876 | ||
| Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production | Q46270888 | ||
| Desensitization in HLA-incompatible kidney recipients and survival. | Q51018759 | ||
| The impact of proteasome inhibition on alloantibody-producing plasma cells in vivo. | Q53271043 | ||
| Combined heart and liver transplantation: protection of the cardiac graft from antibody rejection by initial liver implantation. | Q53345375 | ||
| Two novel assays of alloantibody-secreting cells demonstrating resistance to desensitization with IVIG and rATG. | Q53506317 | ||
| A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. | Q53639822 | ||
| Overcoming a positive crossmatch in living-donor kidney transplantation. | Q55036659 | ||
| Segmented regression analysis of interrupted time series studies in medication use research | Q74601008 | ||
| Tutorial in Biostatistics: Evaluating the impact of 'critical periods' in longitudinal studies of growth using piecewise mixed effects models | Q77578861 | ||
| Transplanting patients with a positive donor-specific crossmatch: a single center's perspective | Q81143143 | ||
| Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year | Q83659526 | ||
| Prospective iterative trial of proteasome inhibitor-based desensitization | Q86384946 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | desensitization | Q2700499 |
| P304 | page(s) | 1222-1227 | |
| P577 | publication date | 2017-06-01 | |
| P1433 | published in | Transplantation | Q15730500 |
| P1476 | title | 32 Doses of Bortezomib for Desensitization Is Not Well Tolerated and Is Associated With Only Modest Reductions in Anti-HLA Antibody | |
| P478 | volume | 101 |
| Q52401610 | Antibody-mediated rejection: New approaches in prevention and management. |
| Q88663316 | Contemporary Strategies and Barriers to Transplantation Tolerance |
| Q30397952 | Desensitization: Overcoming the Immunologic Barriers to Transplantation |
| Q89746966 | Evaluation and Treatment of Acute Rejection in Kidney Allografts |
| Q89472835 | HLA in transplantation |
| Q38945149 | Humoral Compensation after Bortezomib Treatment of Allosensitized Recipients |
| Q50993047 | Kidney Transplant With Low Levels of DSA or Low Positive B-Flow Crossmatch: An Underappreciated Option for Highly Sensitized Transplant Candidates. |
| Q93142076 | Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant |
| Q89777486 | Successful desensitization with proteasome inhibition and costimulation blockade in sensitized nonhuman primates |
| Q91819183 | Transplant outcomes in positive complement-dependent cytotoxicity- versus flow cytometry-crossmatch kidney transplant recipients after successful desensitization: a retrospective study |
Search more.